重性抑郁多基因评分与双相障碍患者锂盐反应相关
该研究利用2586例接受锂盐治疗的双相障碍患者数据,计算重性抑郁多基因评分(PGS),发现低抑郁多基因负荷者锂盐反应更好(多族裔样本OR=1.54,欧洲样本OR=1.75),亚洲样本效应同向但未达显著。结果提示遗传因素贡献于锂盐反应,支持锂盐反应性生物型概念。
要点
- 低重性抑郁多基因负荷的双相障碍患者锂盐反应更佳。
- 多族裔样本中最低与最高PGS四分位比较OR=1.54(95%CI 1.18-2.01)。
- 欧洲样本OR=1.75(95%CI 1.30-2.36),亚洲样本未显著。
核心结论
- 重性抑郁多基因评分与双相障碍患者锂盐治疗反应显著相关,低多基因负荷者更可能反应良好。
研究设计与样本
- 研究纳入2586例接受锂盐治疗的双相障碍患者,来自锂遗传学联盟(ConLi+Gen)研究。
- 使用精神病学基因组联盟(PGC)重性抑郁GWAS汇总统计(135,458例病例和344,901例对照)计算不同p值阈值的加权多基因评分。
- 锂盐反应采用Alda量表连续评分和二分类结局(反应者vs非反应者),用线性回归和二元逻辑回归分析,在全样本及欧洲、亚洲亚组中进行。
主要发现
- 重性抑郁多基因评分在多个p值阈值下与锂盐治疗反应显著相关,见于多族裔、欧洲或亚洲人群。
- 最低与最高PGS四分位比较,多族裔样本OR=1.54(95%CI: 1.18-2.01),欧洲样本OR=1.75(95%CI: 1.30-2.36)。
- 亚洲样本效应量同向:OR=1.71(95%CI: 0.61-4.90),但未达统计学显著。
- PGS十分位比较显示高抑郁遗传负荷与较低锂盐反应相关的类似趋势。
关键数值与推荐
- 锂盐反应定义:Alda量表连续评分及二分类结局(反应者vs非反应者)。
- 重性抑郁PGS基于PGC GWAS汇总统计(135,458例病例和344,901例对照)加权计算。
- 最低vs最高PGS四分位比较:多族裔样本OR=1.54(95%CI: 1.18-2.01),欧洲样本OR=1.75(95%CI: 1.30-2.36),亚洲样本OR=1.71(95%CI: 0.61-4.90)。
临床怎么用
- 重性抑郁多基因评分可能辅助识别更可能对锂盐反应良好的双相障碍患者。
- 低抑郁多基因负荷提示锂盐反应可能性较高,高负荷提示反应可能较低。
- 亚洲人群效应未达显著,临床解读需谨慎。
局限性
- 亚洲样本中关联未达统计学显著(OR=1.71,95%CI: 0.61-4.90)。
- 研究为观察性关联分析,未报告因果推断或临床干预验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap between depression and bipolar disorder, we investigated whether a polygenic susceptibility to major depression is associated with response to lithium treatment in patients with BD. Weighted polygenic scores (PGSs) were computed for major depression (MD) at different GWAS p value thresholds using genetic data obtained from 2586 bipolar patients who received lithium treatment and took part in the Consortium on Lithium Genetics (ConLi+Gen) study. Summary statistics from genome-wide association studies in MD (135,458 cases and 344,901 controls) from the Psychiatric Genomics Consortium (PGC) were used for PGS weighting. Response to lithium treatment was defined by continuous scores and categorical outcome (responders versus non-responders) using measurements on the Alda scale. Associations between PGSs of MD and lithium treatment response were assessed using a linear and binary logistic regression modeling for the continuous and categorical outcomes, respectively. The analysis was performed for the entire cohort, and for European and Asian sub-samples. The PGSs for MD were significantly associated with lithium treatment response in multi-ethnic, European or Asian populations, at various p value thresholds. Bipolar patients with a low polygenic load for MD were more likely to respond well to lithium, compared to those patients with high polygenic load [lowest vs highest PGS quartiles, multi-ethnic sample: OR = 1.54 (95% CI: 1.18-2.01) and European sample: OR = 1.75 (95% CI: 1.30-2.36)]. While our analysis in the Asian sample found equivalent effect size in the same direction: OR = 1.71 (95% CI: 0.61-4.90), this was not statistically significant. Using PGS decile comparison, we found a similar trend of association between a high genetic loading for MD and lower response to lithium. Our findings underscore the genetic contribution to lithium response in BD and support the emerging concept of a lithium-responsive biotype in BD.
引用
- Amare AT, Schubert KO, Hou L, et al. Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Mol Psychiatry. 2020. PMID: 32203155. doi:10.1038/s41380-020-0689-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。